The Story So Far: The UK’s New Licensing And Access Pathway
More Than 35 'Innovation Passports' Have Been Issued
As the UK’s new pathway for innovative drugs approaches the end of its first year of operation, representatives of the national regulatory agency and England’s HTA body assess progress so far, including the greater role assigned to patients in the system.
You may also be interested in...
The option of receiving early, joined-up advice from HTA bodies in England, Scotland and Wales is among several tools that companies can use if their product is admitted to the UK’s Innovative Licensing and Access Pathway.
The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.
The number of “innovation passports” handed out by the UK Medicines and Healthcare products Regulatory Agency is growing as more companies seek to take advantage of the tools and flexibilities available under the ILAP. InnoSkel is one such company.